Adjuvanted vaccines and AIT products distinctly modulate immune metabolism

Background Currently, the number of adjuvants authorized for allergen-specific immunotherapy (AIT) is limited, and their immune-metabolic effects are largely unknown. To identify promising adjuvants for AIT, we systematically compared representative examples of all commercially available adjuvants used in vaccines and AIT products that are authorized for human use. Methods Mouse myeloid dendritic cells (mDCs) were stimulated with different vaccines and AIT products and analyzed for their activation status (cytokine secretion and CD69 and MHCII expression), metabolic state (metabolic flux analyses, Warburg metabolism, and glucose consumption), and the underlying mechanisms (Western blot and inhibitor experiments). Results Vaccines and AIT products induced distinct immune-metabolic profiles, characterized by either: 1) no detectable mDC activation [lipid nanoparticle (LNP)-formulated vaccine]; 2) modest activation of glucose metabolism (GM) with prominent CCL2 secretion (alum-adjuvanted AIT product); 3) strongly increased GM and chemokine CCL2 secretion (MF59-adjuvanted vaccine); 4) activation of GM with pre-dominantly pro-inflammatory cytokines [monophosphoryl lipid A (MPL)- and aluminum/QS-21-adjuvanted vaccines]; 5) transient metabolic activation with pro- and anti-inflammatory cytokines (MPL- and l -tyrosine-adjuvanted AIT product); or 6) activation of GM paralleled by anti-inflammatory IL-10 secretion (CpG1018-adjuvanted vaccine). The effects were at least in part adjuvant-mediated and independent of either antigen or buffer. Mechanistically, the vaccines were shown to trigger nuclear factor kappa B (NFκB), mitogen-activated protein (MAP) kinase, and mammalian target of rapamycin (mTOR) signaling. The activation of mTOR was shown to contribute to the observed immune-metabolic effects. Conclusion Our study provides a comparative analysis of the immune-metabolic effects of all currently available adjuvants authorized for human use in Germany in mouse mDCs, improving our mechanistic understanding and paving the way for further studies that may enable their safe and efficient application also beyond the current scope of use.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-13
DOI
https://doi.org/10.3389/fimmu.2026.1939734
Primary Topic
Immunotherapy and Immune Responses
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Adjuvanted vaccines and AIT products distinctly modulate immune metabolism

Daniel Strecker, Teresa Enrique-Benedito, Stefan Schülke, Sascha Döring et al.
2 links
Frontiers in Immunology
Immunotherapy and Immune Responses
article

Adjuvanted vaccines and AIT products distinctly modulate immune metabolism

Daniel Strecker, Teresa Enrique-Benedito, Stefan Schülke, Sascha Döring, Ludger Sandig, Hannah Ruth Schiller, Angelina Eisenhauer
article en

Abstract

Background Currently, the number of adjuvants authorized for allergen-specific immunotherapy (AIT) is limited, and their immune-metabolic effects are largely unknown. To identify promising adjuvants for AIT, we systematically compared representative examples of all commercially available adjuvants used in vaccines and AIT products that are authorized for human use. Methods Mouse myeloid dendritic cells (mDCs) were stimulated with different vaccines and AIT products and analyzed for their activation status (cytokine secretion and CD69 and MHCII expression), metabolic state (metabolic flux analyses, Warburg metabolism, and glucose consumption), and the underlying mechanisms (Western blot and inhibitor experiments). Results Vaccines and AIT products induced distinct immune-metabolic profiles, characterized by either: 1) no detectable mDC activation [lipid nanoparticle (LNP)-formulated vaccine]; 2) modest activation of glucose metabolism (GM) with prominent CCL2 secretion (alum-adjuvanted AIT product); 3) strongly increased GM and chemokine CCL2 secretion (MF59-adjuvanted vaccine); 4) activation of GM with pre-dominantly pro-inflammatory cytokines [monophosphoryl lipid A (MPL)- and aluminum/QS-21-adjuvanted vaccines]; 5) transient metabolic activation with pro- and anti-inflammatory cytokines (MPL- and l -tyrosine-adjuvanted AIT product); or 6) activation of GM paralleled by anti-inflammatory IL-10 secretion (CpG1018-adjuvanted vaccine). The effects were at least in part adjuvant-mediated and independent of either antigen or buffer. Mechanistically, the vaccines were shown to trigger nuclear factor kappa B (NFκB), mitogen-activated protein (MAP) kinase, and mammalian target of rapamycin (mTOR) signaling. The activation of mTOR was shown to contribute to the observed immune-metabolic effects. Conclusion Our study provides a comparative analysis of the immune-metabolic effects of all currently available adjuvants authorized for human use in Germany in mouse mDCs, improving our mechanistic understanding and paving the way for further studies that may enable their safe and efficient application also beyond the current scope of use.

Frontiers in ImmunologyVol. 17
Paul Ehrlich Institut (DE)
Good health and well-being
Immunotherapy and Immune Responses
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon